A Biotech's Guide To Selecting CDMOs: "35 Or 6 To 2"

By Louis Garguilo, Chief Editor, Outsourced Pharma

No disrespect meant to Tom Bliss, veteran pharma and bio executive (e.g., Amgen, Baxter, Kyocera) and most recently CEO of platform-biotech Genisphere, nor James Kadushin, 22-year veteran and (retiring) VP operations/COO at the company, but as I spoke to them recently, I kept recalling Chicago’s iconic ‘70s rock song, “25 or 6 to 4.”

That’s because Bliss and Kadushin were detailing for me how Genisphere went from an original list of “35 or 6 candidate CDMOs to 2 selected” as their development and manufacturing partners. Their description of that process should be music to the ears of any biopharma undergoing or about to go on a CDMO search.